1. Home
  2. LRMR vs PROP Comparison

LRMR vs PROP Comparison

Compare LRMR & PROP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LRMR
  • PROP
  • Stock Information
  • Founded
  • LRMR N/A
  • PROP 2001
  • Country
  • LRMR United States
  • PROP United States
  • Employees
  • LRMR N/A
  • PROP N/A
  • Industry
  • LRMR Biotechnology: Pharmaceutical Preparations
  • PROP Investment Bankers/Brokers/Service
  • Sector
  • LRMR Health Care
  • PROP Finance
  • Exchange
  • LRMR Nasdaq
  • PROP Nasdaq
  • Market Cap
  • LRMR 183.8M
  • PROP 190.0M
  • IPO Year
  • LRMR N/A
  • PROP N/A
  • Fundamental
  • Price
  • LRMR $2.04
  • PROP $5.16
  • Analyst Decision
  • LRMR Strong Buy
  • PROP
  • Analyst Count
  • LRMR 10
  • PROP 0
  • Target Price
  • LRMR $19.60
  • PROP N/A
  • AVG Volume (30 Days)
  • LRMR 911.3K
  • PROP 608.4K
  • Earning Date
  • LRMR 03-24-2025
  • PROP 01-01-0001
  • Dividend Yield
  • LRMR N/A
  • PROP N/A
  • EPS Growth
  • LRMR N/A
  • PROP N/A
  • EPS
  • LRMR N/A
  • PROP N/A
  • Revenue
  • LRMR N/A
  • PROP $7,939,000.00
  • Revenue This Year
  • LRMR N/A
  • PROP $8,816.87
  • Revenue Next Year
  • LRMR N/A
  • PROP N/A
  • P/E Ratio
  • LRMR N/A
  • PROP N/A
  • Revenue Growth
  • LRMR N/A
  • PROP N/A
  • 52 Week Low
  • LRMR $2.07
  • PROP $4.50
  • 52 Week High
  • LRMR $11.20
  • PROP $16.08
  • Technical
  • Relative Strength Index (RSI)
  • LRMR 31.08
  • PROP 38.14
  • Support Level
  • LRMR $2.19
  • PROP $5.15
  • Resistance Level
  • LRMR $2.44
  • PROP $5.99
  • Average True Range (ATR)
  • LRMR 0.18
  • PROP 0.57
  • MACD
  • LRMR -0.01
  • PROP 0.01
  • Stochastic Oscillator
  • LRMR 5.19
  • PROP 39.52

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

About PROP Prairie Operating Co.

Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.

Share on Social Networks: